An indication with important qualifiers
Dronabinol and nabilone are regulated medicines with defined indications that include chemotherapy-related nausea and vomiting in particular circumstances. That is different from evidence for dispensary products, CBD alone, or cannabis as cancer treatment.
Many cannabinoid antiemetic trials predate current multi-drug prevention regimens. Older comparisons can therefore answer a different question from the one faced in modern oncology care.
What current guidance says
The 2024 ASCO guideline found the strongest supportive-care evidence in refractory chemotherapy-induced nausea and vomiting. It advises against replacing cancer-directed treatment with cannabis or cannabinoids and does not support using them to improve cancer control outside a clinical trial.
Adverse effects, interactions, formulation, and concurrent cancer medicines matter. Evidence for one prescription product does not validate every cannabinoid product.
Clinical context comes first
Persistent vomiting during treatment can require prompt oncology assessment. Decisions about prescription cannabinoids belong within the antiemetic plan developed by the treating team, rather than being added without medication review.
Prevention and rescue treatment are different
Oncology teams often plan nausea prevention around the chemotherapy regimen and the patient's risk. Modern combinations of established anti-nausea medicines can be highly effective. A medicine considered after symptoms break through is answering a different question from a first-line preventive treatment.
Older cannabinoid trials were conducted before some current regimens existed. Their results remain relevant, but they cannot be compared with today's care without considering what the control group received.
What regulated cannabinoid medicines contribute
Dronabinol and nabilone have regulated indications connected with chemotherapy-related nausea and vomiting under defined circumstances. Their evidence and warnings belong to those measured medicines, not to every cannabis product.
THC-like effects can include dizziness, sleepiness, changes in mood or perception, and impaired coordination. Those effects may be difficult for a patient who is already fatigued, dehydrated, or taking several medicines.
What current cancer guidance emphasizes
ASCO guidance identifies refractory chemotherapy-related nausea and vomiting as the area with the clearest supportive-care evidence. It does not support replacing effective cancer treatment with cannabis or cannabinoids, and it does not treat patient interest as proof of anticancer benefit.
Evidence for symptom relief should always be separated from claims about slowing a tumour, improving survival, or curing cancer. Those are different outcomes that require different trials.
When symptoms need prompt care
Persistent vomiting can cause dehydration and may interfere with treatment. It can also signal infection, bowel problems, medication effects, or another complication. The oncology team should know when symptoms are not controlled.
Patients should share every cannabis or cannabinoid product with the care team because interactions, sedation, product contents, and treatment timing may matter. This allows symptoms to be addressed without hiding information or delaying established care.



